Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)

被引：0
|
作者：
Schuchardt, C. [1 ]
Kulkarni, H. R. [1 ]
Wiessalla, S. [1 ]
Shahinfar, M. [1 ]
Shafaei, S. [1 ]
Kropf, S. [2 ]
Wester, H. J. [3 ,4 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka GmbH, THERANOST Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Scintomics GmbH, Fuerstenfeldbruck, Germany
[3] Tech Univ Munich, Fac Chem, D-80290 Munich, Germany
[4] Tech Univ Munich, Fac Med, D-80290 Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP291
引用
收藏
页码：S224 / S225
页数：2
相关论文
共 50 条
  • [1] Serial Dosimetry in Peptide Receptor Radionuclide Therapy using Lu-177 DOTATATE or Lu-177 DOTATOC in the same Patient
    Schuchardt, C.
    Kulkarni, H.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S139 - S139
  • [2] Lu-177 HA-DOTATATE for Peptide Receptor Radionuclide Therapy (PRRT): First Results in Patients Concerning Biodistribution, Normal Organ and Tumor Dosimetry
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S224
  • [3] LU-177 DOTATATE THERAPY IN PATIENTS WITH NETS
    Hosking, E.
    McKay, E.
    Browne, E.
    Thomas, D.
    Liauw, W.
    Morris, D.
    Chu, F.
    Hayes, A.
    Butler, P.
    [J]. INTERNAL MEDICINE JOURNAL, 2015, 45 : 18 - 18
  • [4] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Josephine Graf
    Ulrich-Frank Pape
    Henning Jann
    Timm Denecke
    Ruza Arsenic
    Winfried Brenner
    Marianne Pavel
    Vikas Prasad
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 881 - 894
  • [5] Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
    Graf, Josephine
    Pape, Ulrich-Frank
    Jann, Henning
    Denecke, Timm
    Arsenic, Ruza
    Brenner, Winfried
    Pavel, Marianne
    Prasad, Vikas
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 881 - 894
  • [6] Establishing a Lu-177 Dotatate Therapy Program
    Snyder, W.
    Harpool, K.
    Swanson, J. W.
    Schantz, P.
    Phan, A.
    Dick, J. S.
    Cavanaugh, S. X.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E499 - E500
  • [7] Patient release after Lu-177 DOTATATE and Lu-177 PSMA 617 therapies
    Mair, C.
    Warwitz, B.
    Buxbaum, S.
    Virgolini, I. J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S454 - S454
  • [8] Peptide Receptor Radionuclide Therapy with Lu-177 DOTATATE in patients with somatostatin receptor positive tumours
    Kamaleshwaran, K.
    Sudhakar, N.
    Paulvannan, S.
    Vysakh, M.
    Shinto, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S722 - S722
  • [9] Peptide receptor radionuclide therapy using somatostatin receptor antagonists: first results of biodistribution and dosimetry of Lu-177 DOTA-LM3 compared to Lu-177 DOTATOC
    Schuchardt, Christiane
    Kulkarni, Harshad
    Singh, Aviral
    Mueller, Dirk
    Fani, Melpomeni
    Maecke, Helmut
    Baum, Richard
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [10] Lu-177 DOTATATE Retreatment: Efficacy and Toxicity
    Santillan, N.
    Ferreira, B.
    Gnanasegaran, G.
    Navalkisoor, S.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S757 - S757
12345